Clinical trial
A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced…
NCT00190840 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190840 |
|---|---|
| Title | A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer |
| Official title | Open-Label Single-Arm Phase 2 Study of ALIMTA in Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small Cell Lung |
| Intervention type | Drug |
| Interventions | pemetrexed |
| Enrollment | 186 |
| Start date | Sep 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | Australia, China, Egypt, India, Romania, South Korea, Taiwan, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: